Interim data from Phase 1 with single and multiple ascending doses show no safety signals and a generally favorable tolerability profile of AGMB-447 in healthy participants -- -- Pharmacokinetic ...

Orion Pharma announces the initiation of TEADES Phase 2 trial of ODM-212 in Malignant Pleural Mesothelioma (MPM) and Epithelioid Hemangioendothelioma (EHE) ...

Biomed Industries to Advance NA-931 Into Two Global Phase 3 Trials as Monotherapy and in Combination With Semaglutide and Tirzepatide for Obesity Advancing NA-931 into two Phase 3 programs as ...

The FDA has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1 (NT1).

Zai Lab has received approval from China’s National Medical Products Administration (NMPA) for the supplemental new drug ...

A new drug application (NDA) has been submitted to the FDA seeking approval of rusfertide, an investigational hepcidin ...

The FDA has granted breakthrough therapy designation (BTD) to sevabertinib (Hyrnuo, formerly BAY 2927088) for the first-line ...

Incyte INCY announced positive top-line results from a late-stage lymphoma study of Monjuvi/Minjuvi (tafasitamab), a ...

Australian Mines is gearing up to restart drilling at its Flemington scandium-nickel-cobalt project in NSW next month.

Preparing for FDA approval and commercial launch of tividenofusp alfa, Denali’s TransportVehicle™ (TV)-enabled investigational therapy for Hunter ...

QRL-101, an oral small molecule being developed by QurAlis, was safe and reduced nerve-cell overactivity in ALS patients in ...

The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...